CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need.

Researchers from the University of Heidelberg have published a study on more than 60,000 patients in the renowned journal Lancet Digital Health, demonstrating the potential of AI in cardiac medicine.

BioRegio STERN Management GmbH is a partner in the new RehAllianCE project, which is being funded by the EU as part of the Interreg CENTRAL EUROPE program. The focus is on the use of new technologies in rehabilitation to improve patient care. The aim is to increase the innovation capacities of SMEs so that aids such as rehabilitation robots, exoskeletons etc. can be used more quickly.

Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces €4.3M in seed funding. This investment will enable Heidelberg Epignostix to make a substantial leap forward in driving market development for its flagship indication for brain tumor classification.

Baden-Württemberg receives the EU Commission's "Regional Innovation Valley" label - 01/07/2024

Customised healthcare for all: BIOPRO is a partner in the EU project PRECISEU

The EU research project PRECISEU, which started in June 2024 and will run for five years, aims to connect innovation ecosystems across Europe and advance personalised medicine throughout Europe. BIOPRO Baden-Württemberg is one of 25 partner organisations from 11 European countries that are working on the further development of customised healthcare as part of the research project.

Baden-Württemberg receives the EU Commission's "Regional Innovation Valley" label - 01/07/2024

Customised healthcare for all: BIOPRO is a partner in the EU project PRECISEU

The EU research project PRECISEU, which started in June 2024 and will run for five years, aims to connect innovation ecosystems across Europe and advance personalised medicine throughout Europe. BIOPRO Baden-Württemberg is one of 25 partner organisations from 11 European countries that are working on the further development of customised healthcare as part of the research project.

Researchers at University of Galway, the Heidelberg Institute for Theoretical Studies (HITS) Heidelberg University, and Heidelberg University Hospital have created digital babies to better understand infants’ health in their critical first 180 days of life. The international team created computer models that simulate the unique metabolic processes of each baby. The models can help to better understand rare metabolic diseases.

How can we use artificial intelligence (AI) to make comprehensible medical decisions? A new project at the University of Mannheim, which has received funding from the Federal Ministry of Education and Research (BMBF), will analyze this question.

At the finale of the Cyber Valley Days, and Science Minister Petra Olschowski opened the ELLIS Institute Tübingen, heralding the next phase of the AI Innovation Campus. With the world's first ELLIS Institute, Cyber Valley is gaining further radiance. Olschowski also announced at the ceremony that the Karlsruhe Institute of Technology (KIT) is joining the Cyber Valley Community.

Researchers from the Max Planck Institute for Biology Tübingen developed the groundbreaking tool SynTracker. SynTracker expands traditional microbial analysis by considering genomic structural variation to complement existing SNP-based methods. This innovation reveals more precision and depths of microbial strain diversity and evolution.

Gender-specific differences - 18/06/2024

Gender medicine: Why is good healthcare not a matter of course for everyone?

Gender medicine is the study of gender-specific health differences. Many diseases manifest themselves differently in men and women and therapies do not always have the same effect depending on the sex of the patient being treated. There is currently not enough data on these differences. Research teams including the one led by Professor Dr. Dr. Sonja Loges from the University Medical Centre Mannheim and the DKFZ are seeking to change this.

Humboldt Research Award winner Prof. Hao Yan has been conducting research at the 2nd Institute of Physics at the University of Stuttgart since May. He is regarded as one of the world's leading experts in the field of DNA nanotechnology. "My work has many points of commonality with the topics that my colleagues in Stuttgart are focusing on," says Yan. "I have therefore been cooperating with Professor Laura Na Liu's working…

Printing a new cornea during an operation to restore a patient’s eyesight: This groundbreaking step in the fight against corneal disorders is set to become reality with a laser based process using personalized bioink. The method was developed by researchers at the Karlsruhe Institute of Technology (KIT) in collaboration with Carl Zeiss Meditec AG and Evonik Healthcare. Their project won the idea award in this year’s NEULAND innovation contest.

Cancer genomes are the result of diverse mutation processes. Scientists have analyzed the molecular evolution of tumors after exposure to mutagenic chemicals. DNA lesions that persists unrepaired over several cell generations lead to sequence variations at the site of damage. This enabled the researchers to distinguish the contribution of the triggering lesion from that of the subsequent repair in shaping the mutation pattern.

Depending on whether the cell nucleus of an epithelial cell is located on the outer or inner side of the tissue, the genome is more or less acetylated - genes can therefore be translated easier or harder. Scientists from the German Cancer Research Center (DKFZ) have demonstrated this for the first time in the development of the Drosophila wing.

BioRegio STERN Management GmbH was today presented with an award at the Innovation Day for SMEs held by Germany’s Federal Ministry for Economic Affairs and Climate Action. Its “biohymed” project was named the year’s best innovation network under the Central Innovation Programme for SMEs (ZIM).

Invasive infections such as sepsis require immediate and targeted treatment. Experts from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB and group partners have succeeded in establishing a reconceptualized detection principle that can make a crucial contribution to saving lives through fast, ultra-accurate pathogen identification. They have been chosen to receive the 2024 Stifterverband Science Prize for their efforts.

Prof. Dr. Peter Loskill and Dr. Silke Riegger from the 3R Center Tübingen for in-vitro models and animal testing alternatives have been awarded the Ursula M. Händel Animal Welfare Prize 2024. The prize, endowed with 80,000 euros, was awarded to them in Würzburg for the development of organ-on-chip (OoC) systems as an alternative to animal testing.

Festo is expanding its portfolio to include multilayer manifolds made of plastic (bonded manifolds) in order to be able to offer manufacturers of medical and laboratory equipment solutions from a single source. To this end, Festo is taking over the production systems and processes for manufacturing these complex plastic manifolds from Carville, a leading company in this field.

he Robert Bosch Stiftung is celebrating its 60th anniversary in 2024. To commemorate this, the Foundation is holding an anniversary celebration today at its headquarters in Stuttgart. Among the guests are partners from the Foundation's charitable work as well as representatives from politics, business, and society, including members of the Bosch family and company.

The Damietta Server broadens the accessibility to protein design research and its applications in various biotechnological and biomedical fields. Researchers at the Max Planck Institute for Biology Tübingen, the University of Tübingen, and the University Hospital Tübingen have developed a web-based toolkit to accelerate and simplify protein design without needing powerful computers or extensive protein design expertise on the user’s end.

In the current approval round of the German Research Foundation (DFG) Heidelberg University has been successful with six applications for grants to fund major, internationally visible research consortia. The six research consortia − three of them will reach the maximum funding length of twelve years after their extension − are to receive financial resources totalling nearly 87 million euros over a period of four years.

Since 2019, the Research Training Group (RTG) "Intraoperative Multisensoric Tissue Differentiation in Oncology," a collaboration between the University of Stuttgart and the University of Tübingen, has been advancing research in medical technology. With the help of new sensor methods, the researchers want to help make surgical procedures on cancer patients safer and more effective.

The Baden-Württemberg Ministry of Science, Research and Arts (MWK) is supporting medical researchers at Ulm University with start-up funding totalling 600,000 euros. The aim is to establish an EU consortium for the broad therapeutic use of mesenchymal stromal cells. The funding is being awarded as part of the "BEGIN - Participation in major European projects and initiatives" programme.

Scientists from the German Cancer Research Center (DKFZ) and the European Bioinformatics Institute EMBL-EBI, Hinxton, UK, are using the Danish health registers to predict individual risks for 20 different types of cancer with a high degree of accuracy. The prediction model can also be transferred to other healthcare systems.

Innovation in emergency medicine - 23/05/2024

CARL pushes back the boundaries of resuscitation therapy

Few people survive a cardiac arrest; blood stops flowing to the brain and other vital organs and the resulting lack of oxygen causes extensive damage to the body. In response to this, researchers at the University Medical Centre Freiburg and Resuscitec GmbH have developed CARL, an innovative resuscitation system, which – in addition to the oxygen level – adjusts numerous blood parameters to individual patient requirements. This greatly improves…

Together with colleagues from Israel and USA, HITS researcher Frauke Gräter investigates the effects of physical force on the collagen protein in two different animal model systems. Their goal is to measure the effects of mechanoradicals on the integrity of the tissue and the well-being of the organism, with impact on health and aging.

On May 17, 2024, aesco solutions, a leading group for production and development services (CDMO) for medical device companies, and D11Z. Ventures GmbH & Co. KG (formerly Zukunftsfonds Heilbronn) announce the closing of the acquisition of seleon GmbH.

Colorectal cancer differs from patient to patient. That is why scientists are looking for characteristic tumors markers that allow to make predictions about the likely response to certain therapies and the individual prognosis. The aim is to identify colorectal cancer subtypes so that these can then be treated in a customized manner.

How do tumors react to a certain therapeutic approach? Knowing this before the start of a therapy would be of enormous value for people suffering from cancer as well as for the doctors treating them. Researchers have now made this very observation possible for the CAR-T cell therapy. This allows us to individually investigate how exactly these tumor cells react to the planned therapy.

App for tuberculosis diagnosis - 15/05/2024

"Find-TB" aims to improve access to tuberculosis diagnostics

Globally, the majority of children with tuberculosis remain undiagnosed and therefore untreated because their symptoms are categorised incorrectly. Researchers at Heidelberg University Hospital want to develop an app that analyses medical information, risk factors and local surveillance data to calculate individual risk of infection and test those who might be affected with TB as early as possible.

Professor Claudia Denkinger from Heidelberg University's Faculty of Medicine is leading the international collaborative project "BreathForDiagnosis". Researchers from Germany, Italy, South Africa and Romania are working with an industrial partner from Switzerland to develop user-friendly breath tests for the rapid diagnosis of respiratory infections such as tuberculosis.

Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development.

Why 3,000 bars are needed to take a comprehensive look at a protein: Konstanz researchers Frederic Berner and Michael Kovermann present a new high-pressure spectroscopy method to unravel the properties of proteins' native structures.

Activated T cells that carry a certain marker protein on their surface are controlled by natural killer cells. In this way, the body presumably curbs destructive immune reactions. Researchers now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells.

An unexpected discovery surprised a scientist at the Max Planck Institute for Intelligent Systems in Stuttgart: nanometer-sized diamond particles, which were intended for a completely different purpose, shone brightly in a magnetic resonance imaging experiment – much brighter than the actual contrast agent, the heavy metal gadolinium. Could diamond dust one day become a novel contrast agent used for MRI?

Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat. Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone.